Name
GS01-10 - HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated her2-positive metastatic breast cancer
Date & Time
Wednesday, December 6, 2023
Speakers
Virtual Session Link
Total Minutes
8:58
OnDemand Video URL